Sagar Anil Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sagar Anil Patel has a total of 297 co-authors. Here are the top co-authors by number of shared publications:
Ashesh B. Jani
Department of Radiation Oncology, Emory University, Atlanta, GA
15 shared publicationsPretesh R. Patel
Department of Radiation Oncology, Emory University, Atlanta, GA
11 shared publicationsYuan Liu
Biostatistics Shared Resource at Winship Cancer Institute, Emory University, Atlanta, Georgia
8 shared publicationsSubir Goyal
Biostatics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, Ga
7 shared publicationsBruce Hershatter
Department of Radiation Oncology, Emory University, Atlanta, GA
6 shared publicationsBruce W. Hershatter
6 shared publications
Latest Publications
- Open Access
Immune determinants of leuprolide-associated cardiovascular risk in prostate cancer
Background and hypothesis: Leuprolide, the most widely used gonadotropin-releasing hormone receptor (GnRHR) agonist for androgen deprivation therapy (ADT) in prostate cancer (PC), is associated with increased risk of cardiovascular events (CVE), but the underlying mechanisms remain poorly defined. Given the pivotal contribution of circulatory immune components to cardiovascular complications, we hypothesized that leuprolide alters the cardiac immune microenvironment and that pre-existing circulating immune phenotypes determine the patient vulnerability to CVE. Methods: We integrated spatial transcriptomics of coronary plaque and cardiac tissues from leuprolide-treated mice, with longitudinal immune profiling blood leukocytes of PC patients receiving leuprolide. Spatial analyses examined treatment-associated changes in cellular composition, inferred receptor signaling, transcriptional programs and intercellular communication across coronary plaque and non-plaque cardiac compartments. Peripheral blood from 25 patients was profiled longitudinally by multiparametric flow cytometry together with measurement of circulating adipocytokines. Results: Leuprolide selectively reorganized the coronary plaque microenvironment in mice, characterized by altered GnRHR- and androgen receptor-signaling in plaque fibroblasts, organization of T+B lymphoid aggregates, and enrichment of inflammatory M1-like macrophages exhibiting interferon and mesenchymal-remodeling programs. These changes accompanied by non-plaque alteration, particularly ventricular cardiomyocyte hypertrophy in murine heart. Approximately ∼44% of PC patients receiving leuprolide had CD8 + T cell phenotype that associated with treatment-related CVE, including ventricular dysfunctions. A composite signature incorporating Tc1 (type 1 cytotoxic T cells), CD8 + effector-memory, CD8 + transitional-memory and CD8 lo T cell populations distinguished this susceptible phenotype. Conclusions: These findings establish cardiovascular immune remodeling as a framework for leuprolide-associated CVE and nominate pre-existing circulating CD8 + T cell states as candidate biomarkers for prospective ADT-risk stratification. Novelty and Significance: The mechanisms underlying cardiovascular complications of GnRH receptor agonist therapy remain incompletely understood. We combined spatial transcriptomic analysis of coronary plaque and cardiac tissue with longitudinal immune profiling of patients with prostate cancer receiving leuprolide. Leuprolide was associated with a plaque-specific immune responses, involving altered fibroblast GnRH-signaling, increased T+B lymphoid aggregates, and inflammatory M1-like macrophages with interferon and mesenchymal-remodeling programs. In contrast, histologically normal vasculature showed a predominantly M2-like macrophage response. Changes outside the plaque included adipose-stromal remodeling and an increase in hypertrophic ventricular cardiomyocytes. In patients, a pre-existing CD8 + T cells had phenotype associated with treatment-related cardiovascular events, including ventricular dysfunction. A signature comprising Tc1, CD8 + effector-memory, CD8 + transitional-memory, and CD8 lo T cell populations distinguished this immune phenotype. These observations suggest that the cardiovascular response to leuprolide is influenced by both the local tissue environment and the pre-existing systemic immune state. The circulating T-cell signature warrants prospective validation as a potential approach to identify patients who may be more susceptible to cardiovascular complications during androgen deprivation therapy.
Open AccessImmune determinants of leuprolide-associated cardiovascular risk in prostate cancer
Background and hypothesis: Leuprolide, the most widely used gonadotropin-releasing hormone receptor (GnRHR) agonist for androgen deprivation therapy (ADT) in prostate cancer (PC), is associated with increased risk of cardiovascular events (CVE), but the underlying mechanisms remain poorly defined. Given the pivotal contribution of circulatory immune components to cardiovascular complications, we hypothesized that leuprolide alters the cardiac immune microenvironment and that pre-existing circulating immune phenotypes determine the patient vulnerability to CVE. Methods: We integrated spatial transcriptomics of coronary plaque and cardiac tissues from leuprolide-treated mice, with longitudinal immune profiling blood leukocytes of PC patients receiving leuprolide. Spatial analyses examined treatment-associated changes in cellular composition, inferred receptor signaling, transcriptional programs and intercellular communication across coronary plaque and non-plaque cardiac compartments. Peripheral blood from 25 patients was profiled longitudinally by multiparametric flow cytometry together with measurement of circulating adipocytokines. Results: Leuprolide selectively reorganized the coronary plaque microenvironment in mice, characterized by altered GnRHR- and androgen receptor-signaling in plaque fibroblasts, organization of T+B lymphoid aggregates, and enrichment of inflammatory M1-like macrophages exhibiting interferon and mesenchymal-remodeling programs. These changes accompanied by non-plaque alteration, particularly ventricular cardiomyocyte hypertrophy in murine heart. Approximately ∼44% of PC patients receiving leuprolide had CD8 + T cell phenotype that associated with treatment-related CVE, including ventricular dysfunctions. A composite signature incorporating Tc1 (type 1 cytotoxic T cells), CD8 + effector-memory, CD8 + transitional-memory and CD8 lo T cell populations distinguished this susceptible phenotype. Conclusions: These findings establish cardiovascular immune remodeling as a framework for leuprolide-associated CVE and nominate pre-existing circulating CD8 + T cell states as candidate biomarkers for prospective ADT-risk stratification. Novelty and Significance: The mechanisms underlying cardiovascular complications of GnRH receptor agonist therapy remain incompletely understood. We combined spatial transcriptomic analysis of coronary plaque and cardiac tissue with longitudinal immune profiling of patients with prostate cancer receiving leuprolide. Leuprolide was associated with a plaque-specific immune responses, involving altered fibroblast GnRH-signaling, increased T+B lymphoid aggregates, and inflammatory M1-like macrophages with interferon and mesenchymal-remodeling programs. In contrast, histologically normal vasculature showed a predominantly M2-like macrophage response. Changes outside the plaque included adipose-stromal remodeling and an increase in hypertrophic ventricular cardiomyocytes. In patients, a pre-existing CD8 + T cells had phenotype associated with treatment-related cardiovascular events, including ventricular dysfunction. A signature comprising Tc1, CD8 + effector-memory, CD8 + transitional-memory, and CD8 lo T cell populations distinguished this immune phenotype. These observations suggest that the cardiovascular response to leuprolide is influenced by both the local tissue environment and the pre-existing systemic immune state. The circulating T-cell signature warrants prospective validation as a potential approach to identify patients who may be more susceptible to cardiovascular complications during androgen deprivation therapy.
- 18 September 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (11) , 866-872
Risk of androgen deprivation therapy after active surveillance for prostate cancer: A real-world analysis
- 18 September 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (11) , 866-872
Risk of androgen deprivation therapy after active surveillance for prostate cancer: A real-world analysis
- Open Access
- 7 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal – Cardio-Oncology
Statin Use in CHIP–ASCVD Research: Bias, Biology, or Both?
- 7 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal – Cardio-Oncology
Open AccessStatin Use in CHIP–ASCVD Research: Bias, Biology, or Both?
- 31 August 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
18F-fluciclovine PET Imaging of Non-PSMA Expressing High-risk Primary Prostate Cancer
A 67-year-old man with rising PSA and palpable prostate lesion underwent prostate MRI, which showed a large PI-RADS 5 lesion confirmed on biopsy as Gleason score 9 (4+5), grade group 5, prostate cancer. 18 F-DCFPyL PET/CT scan for initial stage showed no significant PSMA avidity in the prostate lesion. 18 F-fluciclovine was obtained for off-label disease staging and management guidance. The high Gleason score prostate lesion showed intense 18 F-fluciclovine avidity. High expression of amino acid transporters and low PSMA expression was confirmed by immunohistochemistry. This case showcases a non-PSMA-avid primary prostate cancer with intense 18 F-fluciclovine, demonstrating the potential of 18 F-fluciclovine PET/CT as an off-label alternative in the uncommon primary prostate cancer without significant PSMA expression.
- 31 August 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
18F-fluciclovine PET Imaging of Non-PSMA Expressing High-risk Primary Prostate Cancer
A 67-year-old man with rising PSA and palpable prostate lesion underwent prostate MRI, which showed a large PI-RADS 5 lesion confirmed on biopsy as Gleason score 9 (4+5), grade group 5, prostate cancer. 18 F-DCFPyL PET/CT scan for initial stage showed no significant PSMA avidity in the prostate lesion. 18 F-fluciclovine was obtained for off-label disease staging and management guidance. The high Gleason score prostate lesion showed intense 18 F-fluciclovine avidity. High expression of amino acid transporters and low PSMA expression was confirmed by immunohistochemistry. This case showcases a non-PSMA-avid primary prostate cancer with intense 18 F-fluciclovine, demonstrating the potential of 18 F-fluciclovine PET/CT as an off-label alternative in the uncommon primary prostate cancer without significant PSMA expression.
- Open Access
- 18 August 2026
- Published by Elsevier in JACC: Cardiooncology
- Vol. 8 (4) , 440-442
Statin Use Attenuates Leuprolide-Associated Coronary Atherosclerosis Progression
- 18 August 2026
- Published by Elsevier in JACC: Cardiooncology
- Vol. 8 (4) , 440-442
Open AccessStatin Use Attenuates Leuprolide-Associated Coronary Atherosclerosis Progression
- 1 June 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 319 (3) , e251874
18 F-Fluciclovine or 68 Ga-PSMA-11 PET/CT–guided Salvage Radiotherapy Changes in Postprostatectomy Biochemical Recurrence: Secondary Analysis of the EMPIRE-2 Trial
Molecular imaging with 18 F-fluciclovine or 68 Ga–prostate-specific membrane antigen–11 had a substantial effect on PET/CT-guided salvage radiotherapy planning in participants with prostate cancer recurrence after prostatectomy.
- 1 June 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 319 (3) , e251874
18 F-Fluciclovine or 68 Ga-PSMA-11 PET/CT–guided Salvage Radiotherapy Changes in Postprostatectomy Biochemical Recurrence: Secondary Analysis of the EMPIRE-2 Trial
Molecular imaging with 18 F-fluciclovine or 68 Ga–prostate-specific membrane antigen–11 had a substantial effect on PET/CT-guided salvage radiotherapy planning in participants with prostate cancer recurrence after prostatectomy.
- Top Cited PapersOpen Access
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 11 (5) , 459-463
Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer
Importance: Androgen deprivation therapy (ADT) for men with prostate cancer (PCa) is associated with cardiovascular (CV) morbidity, yet the biological basis remains unclear. Recent studies have yielded conflicting results regarding the CV safety of gonadotropin-releasing hormone (GnRH) agonists vs antagonists. Objective: To test the hypothesis that ADT is associated with accelerated coronary atherosclerosis and is more prominent with a GnRH agonist compared with a GnRH antagonist. Design, Setting, and Participants: This open-label randomized clinical trial was conducted at 4 centers affiliated with a single academic institution in Atlanta, Georgia. Participants were men with nonmetastatic PCa without prior ADT exposure receiving pelvic radiotherapy with ADT of 6 months duration or longer. Patients were randomly assigned 1:1 to either the GnRH agonist leuprolide or the GnRH antagonist relugolix. Trial enrollment was completed between June 16, 2022, and March 6, 2024. Data analysis was completed between March 31, 2025, and June 23, 2025. Intervention: Pelvic radiotherapy plus either GnRH agonist leuprolide or GnRH antagonist relugolix. Main Outcomes and Measures: The primary end point was change in coronary artery total plaque volume (TPV), measured by coronary computed tomographic angiography completed at baseline and 12 months after ADT initiation. The secondary end point was change in coronary artery noncalcified plaque volume (NCPV). Other outcome measures included change in calcified plaque volume (CPV) and low-attenuation plaque volume (LAPV). Results: Of 65 men enrolled, 62 (31 in each arm) completed all study procedures for analysis. Mean (SD) age was 68.5 (8.5) years, and 35 of 62 participants (56%) were taking statins. Compared with relugolix, leuprolide was associated with a significantly greater 12-month increase in TPV (estimated difference, +68.9 mm 3 ; 95% CI, 23.2-114.5 mm 3 ; P = .02) and NCPV (+64.5 mm 3 ; 95% CI, 31.6-97.3 mm 3 ; P = .004) after adjustment for baseline plaque volume, age, and statin use. There was no significant difference in 12-month change in CPV or LAPV between patients treated with leuprolide vs relugolix. Conclusions and Relevance: In this randomized clinical trial in men with localized PCa treated with radiation plus ADT, the GnRH agonist leuprolide was associated with greater coronary plaque progression within 12 months compared with the GnRH antagonist relugolix. This change was driven by an increase in noncalcified plaque volume and may be mediating ADT-associated CV risk. Trial Registration: ClinicalTrials.gov Identifier: NCT05320406
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 11 (5) , 459-463
Top Cited PapersOpen AccessCoronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer
Importance: Androgen deprivation therapy (ADT) for men with prostate cancer (PCa) is associated with cardiovascular (CV) morbidity, yet the biological basis remains unclear. Recent studies have yielded conflicting results regarding the CV safety of gonadotropin-releasing hormone (GnRH) agonists vs antagonists. Objective: To test the hypothesis that ADT is associated with accelerated coronary atherosclerosis and is more prominent with a GnRH agonist compared with a GnRH antagonist. Design, Setting, and Participants: This open-label randomized clinical trial was conducted at 4 centers affiliated with a single academic institution in Atlanta, Georgia. Participants were men with nonmetastatic PCa without prior ADT exposure receiving pelvic radiotherapy with ADT of 6 months duration or longer. Patients were randomly assigned 1:1 to either the GnRH agonist leuprolide or the GnRH antagonist relugolix. Trial enrollment was completed between June 16, 2022, and March 6, 2024. Data analysis was completed between March 31, 2025, and June 23, 2025. Intervention: Pelvic radiotherapy plus either GnRH agonist leuprolide or GnRH antagonist relugolix. Main Outcomes and Measures: The primary end point was change in coronary artery total plaque volume (TPV), measured by coronary computed tomographic angiography completed at baseline and 12 months after ADT initiation. The secondary end point was change in coronary artery noncalcified plaque volume (NCPV). Other outcome measures included change in calcified plaque volume (CPV) and low-attenuation plaque volume (LAPV). Results: Of 65 men enrolled, 62 (31 in each arm) completed all study procedures for analysis. Mean (SD) age was 68.5 (8.5) years, and 35 of 62 participants (56%) were taking statins. Compared with relugolix, leuprolide was associated with a significantly greater 12-month increase in TPV (estimated difference, +68.9 mm 3 ; 95% CI, 23.2-114.5 mm 3 ; P = .02) and NCPV (+64.5 mm 3 ; 95% CI, 31.6-97.3 mm 3 ; P = .004) after adjustment for baseline plaque volume, age, and statin use. There was no significant difference in 12-month change in CPV or LAPV between patients treated with leuprolide vs relugolix. Conclusions and Relevance: In this randomized clinical trial in men with localized PCa treated with radiation plus ADT, the GnRH agonist leuprolide was associated with greater coronary plaque progression within 12 months compared with the GnRH antagonist relugolix. This change was driven by an increase in noncalcified plaque volume and may be mediating ADT-associated CV risk. Trial Registration: ClinicalTrials.gov Identifier: NCT05320406
- 1 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (4) , 102556
Utilization, Cost, and Subsequent Salvage Treatment of Ablative Therapies for Localized Prostate Cancer in the United States
- 1 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (4) , 102556
Utilization, Cost, and Subsequent Salvage Treatment of Ablative Therapies for Localized Prostate Cancer in the United States
- 14 November 2025
- Published by Elsevier in Brachytherapy
- Vol. 25 (1) , 253-254
Reply to Dedeepya et al. comment on “High-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer”
- 14 November 2025
- Published by Elsevier in Brachytherapy
- Vol. 25 (1) , 253-254
Reply to Dedeepya et al. comment on “High-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer”
- 25 October 2025
- Published by Elsevier in Brachytherapy
- Vol. 25 (1) , 9-14
MRI-guided neurovascular bundle avoidance in high dose rate prostate brachytherapy
- 25 October 2025
- Published by Elsevier in Brachytherapy
- Vol. 25 (1) , 9-14
MRI-guided neurovascular bundle avoidance in high dose rate prostate brachytherapy